Indeed tau has emerged as the possible new target of choice for AD [54] with inhibition of tau phosphorylation and aggregation [55], reduction of tau levels by immune approaches, and microtubule stabilization [54, 56] emerging as novel therapeutic strategies. The gene discussed is MAPT; the disease is Alzheimer disease.